Profilo società
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
- pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases);
- human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas.
At the end of 2024, the group had 52 production sites worldwide.
In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation.
Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).
- pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases);
- human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas.
At the end of 2024, the group had 52 production sites worldwide.
In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation.
Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).
Fonte: Cofisem - Ultimo aggiornamento: 2025-03-25
Dirigenti principali
| Chief Executive Officer | |
| Chief Financial Officer | |
| Director Research & Development | |
| Chief Human Resources Officer | |
| Chief Regulatory & Public Affairs Officer | |
| Head of Investor Relations | |
| General Counsel |
Fonte: Cofisem - Ultimo aggiornamento: 2025-03-25
Dati principali
| Millenium | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 41.081 | 37.817 | 42.997 | 37.761 | 36.041 |
| Income from ordinary activities | 44.286 | 41.618 | 45.389 | 39.175 | 37.369 |
| Operating income | 7.252 | 6.960 | 10.656 | 8.126 | 14.141 |
| Cost of financial indebtedness net | 186 | 25 | 124 | 259 | 225 |
| Equity-accounted companies contribution to income | 60 | -136 | 68 | 39 | 359 |
| Net profit from discontinued activities | 64 | 338 | 0 | ||
| Net income | 5.618 | 5.436 | 8.484 | 6.279 | 12.350 |
| Net income (Group share) | 5.560 | 5.400 | 8.371 | 6.223 | 12.314 |
| Fiscal year end | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - millions | EUR - millions | EUR - millions | EUR - millions | EUR - millions |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
Fonte: Cofisem - Ultimo aggiornamento: 2025-03-25
Informazioni sull'azionariato
| Free float | |
| L'Oréal | |
| BlackRock, Inc. | |
| Employees | |
| Treasury stock |
Fonte: Cofisem - Ultimo aggiornamento: 2025-03-25
Indirizzo
Sanofi
46 Avenue de la Grande Armée
FR-75017 Paris
France
Numero di telefono: +33 (0)1 53 77 40 00
https://www.sanofi.com/fr/investisseurs/
Fonte: Cofisem - Ultimo aggiornamento: 2025-03-25
Contatti
Per supporto nell'aggiornamento del company profile: MyQuestion.Italy@euronext.com.